Get the Stockscreener App
1.01
3.23%
0.0316
After Hours:
.99
-0.02
-1.98%
Tevogen Bio Holdings Inc stock is traded at $1.01, with a volume of 766.05K.
It is up +3.23% in the last 24 hours and down -5.61% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
See More
Previous Close:
$0.9784
Open:
$0.9895
24h Volume:
766.05K
Relative Volume:
0.83
Market Cap:
$182.46M
Revenue:
-
Net Income/Loss:
$52.50M
P/E Ratio:
34.71
EPS:
0.0291
Net Cash Flow:
$-4.13M
1W Performance:
+1.79%
1M Performance:
-5.61%
6M Performance:
-57.38%
1Y Performance:
+2.41%
1-Day Range:
$0.97
$1.03
1-Week Range:
$0.9241
$1.10
52-Week Range:
$0.2556
$3.09
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Compare TVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
1.01 | 182.46M | 0 | 52.50M | -4.13M | 0.0291 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Tevogen Bio Holdings Inc Stock (TVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Initiated | D. Boral Capital | Buy |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest - marketscreener.com
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased ... - Bluefield Daily Telegraph
CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment - The Manila Times
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, ... - Bluefield Daily Telegraph
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment - Yahoo Finance
Tevogen sees launch year oncology business revenue $1B - Yahoo Finance
Tevogen Bio shares surge on revenue forecast By Investing.com - Investing.com Nigeria
Tevogen Bio shares surge on revenue forecast - Investing.com
Tevogen highlights DRS account benefits for shareholders - Investing.com
Tevogen highlights DRS account benefits for shareholders By Investing.com - Investing.com UK
Direct Registration vs Brokerage: Tevogen Reveals Key Benefits for Shareholders - Stock Titan
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - The Manila Times
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - GlobeNewswire
Tevogen CEO Teams with Wall Street Giants to Navigate Biotech Market Volatility at BioNJ Conference - Stock Titan
Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Tevogen shares skyrocket as it projects $1B in revenue for its oncology pipeline - MSN
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? - Benzinga
Tevogen Bio Holdings Inc. Secures $50 Million Agreement with CD8 Technology Services to Enhance R&D and Manufacturing Capabilities - Nasdaq
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and ... - Bluefield Daily Telegraph
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 - GlobeNewswire
Tevogen's Revolutionary Cancer Drug Pipeline Could Generate $14 Billion: Inside the Forecast - Stock Titan
Tevogen Bio revises director resignation process - Investing.com Australia
Tevogen Bio revises director resignation process By Investing.com - Investing.com Nigeria
Tevogen Bio Announces 2025 Annual Meeting - GlobeNewswire
Tevogen Bio Shareholders to Vote on Critical Board Changes at 2025 Annual Meeting - Stock Titan
Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility - marketscreener.com
Tevogen Bio Signs Agreement with CD 8 Technology - TipRanks
Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility - The Manila Times
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility - Bluefield Daily Telegraph
Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility - Benzinga
Tevogen Bio Takes Control of Cell Therapy Production: Major Step Toward Manufacturing Independence - Stock Titan
WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market - The Manila Times
Tevogen Bio Partners with Databricks to Enhance AI-Driven Precision Immunotherapy Development - Nasdaq
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction - TradingView
Tevogen Bio CEO Joins JPMorgan, Cantor Fitzgerald Experts to Reveal Market Liquidity Tactics - Stock Titan
Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints - Seeking Alpha
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump's Initiative to Encourage Pharmaceutical Manufacturing in United States - The Manila Times
Tevogen Takes on Drug Affordability Crisis with New US Manufacturing Division - Stock Titan
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly's Leading AI Biotechs - The Manila Times
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s - Bluefield Daily Telegraph
Tevogen's Game-Changing AI Platform Accelerates T Cell Therapy Breakthroughs - Stock Titan
Tevogen reports high insider ownership amid market volatility By Investing.com - Investing.com South Africa
Tevogen reports high insider ownership amid market volatility - Investing.com Australia
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company's Mission - The Manila Times
Massive 74% Insider Stake Reveals Tevogen Bio Leadership's Unwavering Commitment - Stock Titan
Tevogen Bio Holdings Inc. SEC 10-K Report - TradingView
Tevogen Bio Holdings Delays Annual Report Filing - TipRanks
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast - The Manila Times
Thomas Butler steps down as Biomea CEO - BioCentury
Tevogen Bio's Ambitious $2B Revenue Target Backed by Leadership Excellence and Key Hire - Stock Titan
Tevogen Bio appoints new head of government affairs By Investing.com - Investing.com South Africa
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):